Eli Lilly And Co vs Redwire Corporation — how do they compare? Eli Lilly And Co trades at $1,220.99 (market cap $1.08T), while Redwire Corporation trades at $13.45 (market cap $3.38B). The key difference: Eli Lilly And Co is far larger — about 319.5× Redwire Corporation's market cap, and Eli Lilly And Co pays a 0.57% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals.
| LLY | RDW | |
|---|---|---|
Market Cap | $1.08T | $3.38B |
Sector | Health | Technology |
52-Week High | $1.24K | $25.90 |
52-Week Low | $639.43 | $5.06 |
Enterprise Value | $1.13T | $2.91B |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
RDW trades at $13.49, up 2.82% with strong technical momentum as the stock approaches its consensus price target of $17.50. The company reported record Q2 2026 revenue of $117.1 million and a growing $542.1 million backlog, though it continues to post significant losses with a -57.26% net margin. Analyst sentiment remains overwhelmingly positive with 80% buy ratings, while technical indicators show bullish moving averages but overbought RSI conditions.
The outlook balances rapid revenue growth and strong defense contract momentum against persistent profitability challenges and cash burn. While the defense pivot and space technology positioning offer long-term potential, investors face dilution risk from ongoing financing needs and the company's path to profitability remains uncertain despite improving operational metrics.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →